Chronic lymphocytic leukemia (CLL) occurs mostly in elderly people and is the most common leukemia in the Western world. Generally, it creates more than 30% of all types of leukemia. However, in Denmark the percentages are even higher, at 35%-40% versus the Chinese and Japanese populations, at only 3%-5%. 1,2 According to data from the US National Cancer Institute, in the United States from 1975 to 2005, a median age at time of diagnosis was 72 years. 3 Incidence rates increase with age and are higher among men than women. In 2009, it was expected that in the United States more than 15,900 newly diagnosed patients and approximately 4396 deaths were the result of CLL. 1 In the US white population, the incidence rate of CLL varies from 3.35 to 3.69 in men to 1.61-1.92 in women; in Europe, from 2.2 to 3.36 in men to 0.9-1.52 in women; and in Oceania, studies report incidence rates of 2.81-2.96 in men and 1.41-1.53 in women. 4, 5 In the view of improving the survival of patients with CLL, prevalence of CLL is higher than incidence. 5, 6 According to Rawstron et al, even 3.5% of adults and 8% of the population over 70 years of age have an asymptomatic disease or so-called monoclonal B lymphocytosis. 7 As shown in this data, CLL is probably an underdiagnosed disease, and the real incidence of CLL appears to be higher. In addition, questions regarding the number of treated patients with CLL, the types of therapy administered, and the monitoring of these patients still remain unanswered.
Republic. 8 We focused on trends in incidence rates, diagnostic recognition and reporting, and the therapeutic preferences of our hematologists. Overall survival and progression-free survival analyses were not the aim of the study.
Two questionnaires were distributed to all 14 specialized hematologic departments in our region, and we were pleased that all hematologists completed the questionnaires (see online supplement to this article). The data acquired were merged with the database of the Department of Internal Medicine-Hematology/Oncology in Brno.
The survey was a one-shot survey focusing on the incidence and prevalence of CLL in 2006-2008. In the Czech Republic, every patient with hematologic malignancy is diagnosed and followed at a specialized hematology department. Because all hematologists from our region participated in the study, we can confirm that we captured all individuals with CLL in the South Moravian region.
The treatment data concern all individuals with CLL who were alive the time of this survey.
Results
On August 1, 2008 (the date the analysis was carried out), a total of 540 patients with a diagnosis of CLL had a permanent residence in the South Moravian region. Of the patients, 306 were men, and 234 were women. The men-to-women ratio was 1.3:1. The median age at time of diagnosis was 65 years (range, 33-92 years). The ascertained prevalence of CLL was 48 per 100,000 in 2007. A slight increase in incidence rates was observed from 5. Table 1 .
Treatment for CLL was indicated in 194 patients (36%). Of these, 93 (17%) also underwent the second-line treatment. Out of these 194 patients, 64 patients (33%) were given a fludarabine-based regimen as the first-line treatment, and 40 patients out of the 64 (62.5%) achieved complete remission (CR). Out of the 194 patients indicated for CLL treatment, 74 (38%) received a chlorambucilbased regimen with 12 patients (16% of the 74) achieving CRs. Twenty-eight patients (14% of 194) received a CHOP (doxorubicin/vincristine/prednisone/prednisolone)-like regimen with 8 CRs (29%). Ten patients (5%) received an alemtuzumab regimen with 6 CRs (60%). Eighteen patients (9%) were treated with a combination of rituximab and corticosteroids or corticosteroids alone with 1 CR (6%; Table 2 ). As mentioned above, 93 patients (17%) also underwent second-line treatment: 39 patients (42%) were given a fludarabine-based regimen with 19 CRs (49%); 19 patients (20%) were given chlorambucil with 1 CR (5%); 8 patients (9%) were given a CHOP-like regimen with 1 CR (12.5%); 10 patients (11%) were given alemtuzumab with 4 CRs (40%); and 17 patients (18%) were given corticoid-based treatment with no CR (Table 3) . Thirty patients were treated within clinical trials.
Focusing on the first-line treatment started only in 2007 and 2008, more patients were treated with a fludarabine-based regimen (23 patients) compared with chlorambucil (13 patients), corticosteroids (8 patients), or a CHOP-like regimen (5 patients; Table 4 ). Most patients receiving fludarabine-based regimens were treated in the academic center. In contrast, patients given chlorambucil were especially managed in the local hematologic departments.
In total, out of 540 patients, 287 patients (53%) were followed at the local hematologic departments and 253 (47%) were treated at 1 main hematologic center. The median follow-up of our patients was 56 months (range, 5-126 months). Table 4 Number of Treated Patients Regimen 
Discussion
Actually, the ascertained incidence of CLL in the South Moravian Region is higher than published data from the analysis carried out in the 1990s (Table 5 ). 4, 6 We confirmed that improved diagnostic methods appeared to strongly affect increasing rates of CLL in the population. Flow cytometry, which is determinative of the diagnostic algorithm of CLL, 9,10 was carried out in 97% of the patients in our region. In contrast, the median age at the time of diagnosis is lower than previously published data (65 years vs. 72 years). 3 It is possible that in the past, patients were diagnosed at an advanced stage of the disease, thus, they were older than patients with the asymptomatic CLL. Currently, these patients are probably diagnosed earlier by flow cytometry testing. The examination of new prognostic factors was affected by many circumstances. In our study, flow cytometry, cytogenetic, and molecular examinations were carried out in > 50% of patients. Most were followed in the main hematologic center and had progressive disease. Consequently, in our analysis 40% of the patients were ZAP70 positive and 44% of patients had unmutated IGVH genes. In contrast, lower incidence rates of unfavorable cytogenetic aberrations, such as deletion 17p or 11q, were observed in these patients. 11 This reinforces the assumption that some of the cytogenetic aberrations appear during the treatment of CLL. The treatment of CLL in our region is based on 2 essential drugs: fludarabine and chlorambucil. Overall, more patients were treated with chlorambucil than fludarabine. However, looking at last 2 years of the analysis (2007 and 2008), the majority of patients have been treated with fludarabine-based therapy. Chlorambucil is still preferred among local hematologists.
Conclusion
The ascertained incidence of CLL in our region is higher than the declared incidence in the past, thus CLL appears to be a misdiagnosed and underreported disease. Currently, the crucial examination for the diagnosis of CLL is flow cytometry. Although the treatment was indicated in only one third of our patients with CLL (36%), the new prognostic factors were examined in > 50% of them. In our opinion, new prognostic factors such as IGVH or ZAP70 are helpful to clinicians at time of diagnosis because they can assess the likely time to progression, whereas others such as 17p deletion should be assessed before treatment to ensure that appropriate therapy is provided. 
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